Indications And Dose
Benign gastric ulceration | Duodenal ulceration ▶BY MOUTH ▶Child 1–5 months: 1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day) ▶Child 6 months–2 years: 2–4 mg/kg twice daily ▶Child 3–11 years: 2–4 mg/kg twice daily (max. per dose 150 mg) ▶Child 12–17 years: 150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night ▶Adult: 150 mg twice daily for 4–8 weeks, alternatively 300 mg once daily for 4–8 weeks, dose to be taken at night Chronic episodic dyspepsia ▶BY MOUTH ▶Adult: 150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night NSAID-associated gastric ulceration ▶BY MOUTH ▶Adult: 150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night NSAID-associated duodenal ulcer ▶BY MOUTH ▶Adult: 300 mg twice daily for 4 weeks, to achieve a higher healing rate Prophylaxis of NSAID-associated gastric ulcer | Prophylaxis of NSAID-associated duodenal ulcer ▶BY MOUTH ▶Adult: 300 mg twice daily Gastro-oesophageal reflux disease ▶BY MOUTH ▶Adult: 150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night Moderate to severe gastro-oesophageal reflux disease ▶BY MOUTH ▶Adult: 600 mg daily in 2–4 divided doses for up to 12 weeks Long-term treatment of healed gastro-oesophageal reflux disease ▶BY MOUTH ▶Adult: 150 mg twice daily Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics ▶BY MOUTH ▶Adult: 150 mg, dose to be given at onset of labour, then 150 mg every 6 hours Gastric acid reduction (prophylaxis of acid aspiration) in surgical procedures ▶INITIALLY BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION ▶Adult: 50 mg, to be given 45–60 minutes before induction of anaesthesia, intravenous injection diluted to 20 mL and given over at least 2 minutes, alternatively (by mouth) 150 mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening Prophylaxis of stress ulceration ▶INITIALLY BY SLOW INTRAVENOUS INJECTION ▶Adult: 50 mg every 8 hours, dose to be diluted to 20 mL and given over at least 2 minutes, then (by mouth) 150 mg twice daily, may be given when oral feeding commences Reflux oesophagitis and other conditions where gastric acid reduction is beneficial ▶BY MOUTH ▶Child 1–5 months: 1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day) ▶Child 6 months–2 years: 2–4 mg/kg twice daily ▶Child 3–11 years: 2–4 mg/kg twice daily (max. per dose 150 mg); increased to up to 5 mg/kg twice daily (max. per dose 300 mg), dose increase for severe gastro- oesophageal disease ▶Child 12–17 years: 150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night, then increased if necessary to 300 mg twice daily for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease, alternatively increased if necessary to 150 mg 4 times a day for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease Conditions where reduction of gastric acidity is beneficial and oral route not available ▶BY INTRAMUSCULAR INJECTION ▶Adult: 50 mg every 6–8 hours ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: 50 mg, dose to be diluted to 20 mL and given over at least 2 minutes; may be repeated every 6–8 hours l UNLICENSED USE ▶In children Oral preparations not licensed for use in children under 3 years. ▶In adults Doses given for prophylaxis of NSAID-associated gastric or duodenal ulcer, and prophylaxis of stress ulceration, are not licensed.
PDF pages 102, 103